A clinical trial sponsored by the National Institutes of Health (NIH) has been initiated at various sites across the US to study kidney transplants between HIV patients.

The HOPE in Action multicentre kidney study aims to assess possible transplant-related and HIV-related complications in recipients after surgery.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The HIV Organ Policy Equity (HOPE) Act passed in 2013 permits transplantation of organs from donors with HIV into qualified recipients suffering from end-stage organ failure and HIV.

HIV patients are at a higher risk of end-stage liver and kidney disease due to damage caused by the virus, its co-infections, and associated comorbidities such as hepatitis B and C, hypertension and diabetes mellitus. Some antiretroviral drugs used in HIV treatment also cause toxicity.

“If proven safe and effective in our study, kidney transplants between people with HIV may result in people living with HIV receiving donated organs sooner and the overall organ transplant waiting list shrinking.”

The HOPE study will involve 160 kidney transplants, of which 80 will be kidneys from deceased donors who had HIV, and the control group will be deceased donors without HIV.

During the trial, recipients will be monitored for organ failure or rejection, the failure of previously effective HIV medications, disease-related complications, psychological and social responses, and the potential development of HIV superinfection.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Principal investigator Christine Durand said: “If proven safe and effective in our study, kidney transplants between people with HIV may result in people living with HIV receiving donated organs sooner and the overall organ transplant waiting list shrinking, to the benefit of everyone who needs a kidney transplant, regardless of HIV status.”

The organisation intends to support another similar trial, called the HOPE in Action Multicenter Liver Study, which will investigate the safety and efficacy of liver transplantation between HIV patients.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact